BioCentury
ARTICLE | Clinical News

Zafgen's beloranib leads to significant weight loss

November 16, 2013 2:25 AM UTC

Zafgen Inc. (Cambridge, Mass.) presented final 12-week data on Friday from 122 evaluable patients in a Phase IIa trial evaluating subcutaneous beloranib ( ZGN-440) to treat obesity. Twice-weekly 0.6, 1.2 and 2.4 mg subcutaneous beloranib each met the co-primary endpoint of greater mean weight loss from baseline to week 12 vs. placebo (5.5, 6.9 and 10.9 kg, respectively, vs. 0.4 kg, p<0.0001 for all). The double-blind, Australian trial enrolled 147 severely obese patients with and without Type II diabetes who were allowed to eat normally and were not counseled to change their exercise habits. Data were presented at the Obesity Week meeting in Atlanta.

In July, Zafgen reported data from a pre-specified interim analysis of the first 19 patients to complete 12 weeks of treatment in the trial. The company also said safety data show beloranib is generally well tolerated with no serious adverse events (see BioCentury, July 22). ...